Abstract: . . .  Germany 1998 GW Pharmaceuticals Plc UK 1998 Actelion Pharmaceuticals Ltd. Switzerland 1997 Biogemma S.A.S. France 1997 Biotage AB Sweden 1997 Intercell AG Austria 1997 Vectura Limited UK 1997 Cytos Biotechnology AG Switzerland 1995 ProStrakan Group Limited UK 1995 MediGene AG Germany 1994 Advanced Medical Solutions Group Plc  . . .
. . .  Biotechnology in Europe: 2006 Comparative study Critical I comparative study for EuropaBio The Colin Sanders Innovation Centre Mewburn Road Banbury OX16 9PA United Kingdom Tel: 1295 817635 Fax: 1295 817636 E-mail: enquiries@criticali.net Av. de l’Armée . . .
. . .  This exercise generated the following profiles for European and US “typical” companies. (See Table overleaf) Elite companies Page 17 Critical I comparative study for EuropaBio 18 — © Critical I 2006 The Elite European Companies Europe - the typical company (Financial data in €m) Age (years) 0-2 3-5 6-10 11-15 Employees 9 17 28 41 R&D employees 9 11 17 18 R&D Spend  . . .
. . .  benchmark, we are asking it to do 4 times better than the average European firm. This exercise generated the following profiles for European and US “typical” companies. (See Table overleaf) Elite companies Page 17 Critical I comparative study for EuropaBio 18 — © Critical I 2006 The Elite European Companies Europe - the typical company (Financial data in €m) Age (years) 0-2 3-5 6-10 11-15 Employees 9 17  . . .
. . .  are asking it to do 4 times better than the average European firm. This exercise generated the following profiles for European and US “typical” companies. (See Table overleaf) Elite companies Page 17 Critical I comparative study for EuropaBio 18 — © Critical I 2006 The Elite European Companies Europe - the typical company (Financial data in €m) Age (years) 0-2 3-5 6-10 11-15 Employees 9 17 28 41 . . .
--3000,5,300,2968,64660